NicOx's revenues fall, but naproxcinod on track
This article was originally published in Scrip
Executive Summary
NicOx's first-quarter revenues fell by 70% to €420,000, which mainly came from research funding from its deal with Pfizer to identify nitric oxide-donating compounds for diabetic retinopathy.